ProHeart 12 spotlights compliance in canine heartworm prevention
Bottom line
Zoetis is continuing to position ProHeart 12, its extended-release injectable moxidectin product for dogs, as a compliance-focused preventive that delivers 12 months of heartworm protection in a single veterinary-administered dose. The sponsored Veterinary Practice News coverage emphasizes the product’s “tasty, tough, broad, fast” positioning around parasite prevention, while official labeling and FDA records show ProHeart 12 is approved for dogs 12 months and older to prevent heartworm disease for a full year, and is also indicated for the treatment of existing larval and adult hookworm infections. FDA approved the product in 2019, and Zoetis says it remains the only FDA-approved canine heartworm preventive that provides a full year of protection with one injection. (veterinarypracticenews.com)
Why it matters: For veterinary professionals, the real story is compliance. Heartworm prevention often fails because monthly dosing is missed, and ProHeart 12 shifts that responsibility into the clinic, where administration is documented and gaps in protection can be reduced. That may be especially relevant in high-risk regions and for practices trying to simplify preventive discussions with pet parents, though appropriate patient selection, weight-based dosing, and attention to labeled safety information remain essential. Published studies and FDA materials describe strong efficacy data and a well-defined safety framework, but they also reflect the product’s history of risk management and the need for veterinary oversight. (pmc.ncbi.nlm.nih.gov)
What to watch: Watch for how aggressively clinics incorporate annual injectable prevention into wellness workflows, especially as manufacturers compete on convenience, adherence, and broader parasite coverage. (veterinarypracticenews.com)
Key facts
- Brand
- ProHeart 12
- Active ingredient
- moxidectin
- Species
- dogs
- Age indication
- 12 months and older
- Primary indication
- prevention of heartworm disease for 12 months
- Additional indication
- treatment of existing larval and adult hookworm infections
- Administration
- single in-clinic injection by a veterinarian
- FDA approval
- 2019
Zoetis is using a fresh trade-media push to spotlight ProHeart 12, an extended-release injectable moxidectin product for dogs that provides 12 months of heartworm prevention with a single in-clinic dose. The sponsored Veterinary Practice News article frames the message around convenience, broad protection, and speed, but the underlying commercial and clinical proposition is straightforward: move heartworm compliance from the home to the hospital. (veterinarypracticenews.com)
That message builds on a product with a longer regulatory and clinical history than the promotional copy suggests. FDA approved ProHeart 12 in 2019 for dogs 12 months of age and older for prevention of heartworm disease caused by Dirofilaria immitis for 12 months. The approval followed years of development work around the ProHeart platform, including earlier safety scrutiny and risk-management controls associated with ProHeart 6. FDA’s approval materials make clear that veterinary administration, training, and labeling safeguards were part of the product’s path back into broader use. (fda.gov)
The key product details are important for clinicians. According to FDA labeling and DailyMed, ProHeart 12 is administered by veterinarians as an extended-release injectable suspension and should be used in dogs 12 months and older. When replacing a monthly heartworm preventive, it should be given within one month of the last dose to avoid a gap in protection. In addition to heartworm prevention, Zoetis says the product is indicated for treatment of existing larval and adult hookworm infections caused by Ancylostoma caninum and Uncinaria stenocephala. (dailymed.nlm.nih.gov)
The evidence base supporting that pitch is fairly robust. A peer-reviewed efficacy paper reported 100% prevention of heartworm disease for 12 months in both laboratory and natural exposure field studies, while a separate safety paper described the formulation as well-tolerated in target-animal studies. Another review on moxidectin and heartworm prevention argues that long-acting injectable products may be especially useful in the face of persistent adherence problems and emerging macrocyclic lactone resistance concerns, because they eliminate missed monthly doses over the covered interval. That said, those are still manufacturer-linked or product-specific data streams, so clinicians will likely continue to weigh them alongside their own case mix, regional parasite pressure, and patient risk profiles. (pmc.ncbi.nlm.nih.gov)
Industry reaction, at least in the available trade and manufacturer-facing materials, centers less on controversy than on workflow and compliance. Zoetis markets ProHeart 12 as putting compliance “in your control,” and the Veterinary Practice News sponsored content echoes that theme. In practical terms, that aligns with a broader preventive-care trend: products that reduce the number of decisions a pet parent has to remember at home may improve persistence, especially in busy households or in practices serving clients with inconsistent refill histories. (veterinarypracticenews.com)
Why it matters: For veterinary teams, ProHeart 12 is less about novelty than about leverage. A once-yearly injectable can turn heartworm prevention into a scheduled medical event tied to wellness care, inventory planning, and documented compliance. That may help practices reduce preventable lapses, strengthen preventive recommendations, and create a clearer standard of care conversation with pet parents. It also gives clinicians another option for dogs that struggle with oral or topical adherence, though it requires confidence in patient screening, timing, and counseling around adverse-event reporting and labeled use. (dailymed.nlm.nih.gov)
There’s also a competitive angle. The preventive market is increasingly shaped by convenience claims, broader parasite coverage, and clinic-controlled administration. While ProHeart 12’s core differentiator remains year-long heartworm protection, the surrounding messaging suggests manufacturers see compliance as a strategic battleground, not just a clinical footnote. Practices may find that these products resonate most when framed not as premium add-ons, but as tools to close known prevention gaps. That is an inference based on the product’s positioning and the published compliance literature. (pmc.ncbi.nlm.nih.gov)
What to watch: Watch for continued marketing around annualized prevention, possible expansion of bundled parasite-control strategies, and whether more clinics build injectable prevention into routine annual wellness protocols over the next 12 to 24 months. (veterinarypracticenews.com)